Anti-Cancer Drugs: Alkalyting Agents Flashcards
The next set of drugs to cover are the Alkylating Agents. What is the MOA of these drugs?
Alkylations of DNA within the nucleus represent the major interactions that lead to cell death
–major site of alkylation within DNA is the N7 position of guanine
These interactions can occur on a single strand or on both strands of DNA through cross-linking, as most major alkylating agents are bifunctional, with two reactive groups. Alkylation of guanine can result in miscoding through: abnormal base pairing with thymine and depurination by excision of guanine residues which leads to DNA strand breakage through scission of the sugar phosphate backbone of DNA
What kind of cells are most susceptible to Alkylating agents?
Replicating cells
–in the late G1 and S phases of the cell cycle
What is the mechanism of resistance of Alkylating agents?
- Increased capability to repair DNA lesions through increased expression and activity of DNA repair enzymes.
- Decreased transport of the alkylating drug into the cell.
- increased expression or activity of glutathione and gluthathione associated proteins, which are needed to conjugate the alkylating agent or glutathione S transferase activity, which catalyzes the conjugation.
What are the adverse effects of Alkylating agents?
Dose related and occur in rapidly growing tissues (bone marrow)
N/V: pre treat with 5-HT3 receptor antagonists (ondansetron)
Potent Vesicants and can damage tissues at the site of administration as well as produce systemic toxicity
Carcinogenic (secondary malignancies) – AML
Alkylating agents are divided into different classes:
- Nitrogen Mustards:
- -cyclophosphamide, Ifosfamide, Mechlorethamine, Melphalan - Nitrosoureas:
- -Carmustine and Lomustine - Alkyl Sulfonates:
- -Busulfan - Methylhydrazines:
- -Procarbazine - Triazines:
- -Dacarbazine (DTIC)
Lets discuss each drug within the Alkylating classes individually. First up are the Nitrogen Mustards. The first drug to discuss in this class is cyclophosphamide. What are the pharmacokinetics?
Oral or IV routes with equal clinical efficacy
Activated by P450 (CYP2A6,2B6,3A4,3A5,2C9,2C18,2C19 with 2B6 displaying the highest 4 hydroxylase activity. These active metabolites are delivered to both tumor and normal tissue, where non-enzymatic cleavage of aldophoshpamide to cytotoxic forms phosphoramide mustard and acrolein occurs.
Liver is protected through enzymatic formation of the inactive metabolites
What are the clinical applications and AE of cyclophosphamide?
Clinical:
–breast, ovarian, non hodgkins lymphoma, CLL, soft tissue sarcoma, neuroblastoma, Wilm’s tumor and rhabdomyosarcoma
AE:
–NV, bone marrow suppression (pancytopenia)
–hemorrhagic cystitis: Acrolein is responsible for the hemorrhagic cystitis!! Can be prevented by parenteral administration of Mesna
Moving on to the next Nitrogen Mustard Alkylating Agent is Ifosfamide. What are the PK and Adverse effects?
PK: --analog of cyclophosphamide --Prodrug (activated by CYP450 3A4) --IV AE: --NV --Bone marrow depression --Nephrotoxicity, Hemorrhagic cystitis and alopecia (give Mesna for the cystitis) Greater extent of side effects than cyclophosphamide
The third Nitrogen Mustard Alkylating Agent is Mechlorethamine. What are the PK, Clinical and AE?
PK: --stable --powerful vesicant (IV) --drug not excreted Clinical: --Hodgkins Lymphoma AE: --severe bone marrow depression and n/v
The fourth and final Nitrogen Mustard Alkylating Agent is Melphalan. What are the AE and clinical applications?
AE:
–Bone marrow suppression, hepatotoxicity, pulmonary fibrosis
Clinical:
Multiple Myeloma
The next class of Alkylating Agents are the Nitrosoureas (carmustine and lomustine) , what are the PK of this class of drugs?
Carmustine = IV
Lomustine = oral
–both require biotransformation, which occurs by nonenzymatic decomposition, or metabolites with both alkylating and carbamoylating activities.
HIGHLY LIPID SOLUBLE and readily CROSS THE BBB
Urinary excretion
What are the clinical applications, AE and resistance for the nitrosoureas?
Clinical:
–Brain Tumors (Cross BBB)
–Lymphomas
AE:
–myelosuppression, renal failure, pulmonary fibrosis
Resistance:
–non cross resistant with other alkylating agents
Third class of Alkylating Agents are the Alkyl Sufonates, which includes Busulfan. What are the clinical applications and AE?
Clinical:
—chronic Myelogenous Leukemia
AE:
—N/V, Bone Marrow suppression and Pulmonary Fibrosis
The fourth class of Alkylating agents are the Methylhydrazines, which include Procarbazine, what are the clinical applications, PK and AE?
Clinical: ---Hodgkins and Non-Hodgkins --Brain Tumors PK: --Oral AE: --One metabolite is a weak monoaminse oxidase (MAO) inhibitor and adverse events can occur when procarbazine is given with other MAO inhibitors as well as sympathomimetic agents and tyramine containing foods. Carcinogenic potential is higher
The fifth and final class of Alkylating Agents are the Triazines, which include Dacarbazine (DTIC). What are the PK, Clinical and AE?
PK: ---IV --Potent Vesicant Clinical: --Malignant melanoma, Hodgkins Lymphoma, Soft Tissue Sarcoma and Neuroblastoma AE: --Myelosuppression and N/V